… Gefitinib showed a progression-free survival (PFS) advantage over chemotherapy as a
first-line therapy in 3 randomized phase III trials in patients with EGFR mutant lung …

… in improving the efficacy of erlotinib. The Cancer and Leukemia Group B trial 30406 was
a randomized phase 2 clinical trial that investigated erlotinib alone or with carboplatin and …

… To some extent, the conclusion of the present study was almost the same as that of the
earlier randomised phase II study, in which gefitinib and erlotinib showed similar efficacy and …

… The potential for combining EGFR TKIs with cytotoxic drugs was initially investigated in four
randomized phase III trials. In these studies, concurrent administration of erlotinib or gefitinib …

… and in combination with erlotinib; it demonstrated a … , randomized phase II trial to prospectively
compare the progression-free survival (PFS) of erlotinib plus tivantinib with erlotinib plus …

… trial compared erlotinib with placebo in previously treated patients with advanced NSCLC and
showed significantly superior survival for erlotinib… conducted a randomized phase II trial to …

… Our prospective, randomized phase II study of patients with NSCLC who previously … that
demonstrated entinostat combined with erlotinib enhances the effect of erlotinib alone and can …

… We hypothesized that erlotinib would be efficacious in the adjuvant setting. … A phase III US
intergroup trial of adjuvant erlotinib in EGFRm-positive NSCLC is actively enrolling patients. …

… for the erlotinib group and 11·5 months for the placebo group, median PFS was significantly
longer with erlotinib than with placebo: 12·3 weeks for patients in the erlotinib group versus …

… -label, phase III study from Japan. Because gefitinib failed to show noninferiority to docetaxel
in the V15-32 trial, we investigated the efficacy and tolerability of erlotinib versus docetaxel …